—

Roivant Sciences Ltd (ROIV) — the peer cohort

As of 2026-10-12 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Roivant Sciences Ltd ranks 7 of 7 in its cohort on the Closelooknet composite (36/100) — the cohort is led by Halozyme Therapeutics Inc at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
ROIV Roivant Sciences Ltd 36 67 20 37 info 18.6%
HALO Halozyme Therapeutics Inc 74 94 94 48 ok 4.9%
ARGX.BR Argen-X 63 56 75 29 info 20.7%
ONC BeiGene, Ltd. 63 76 62 30 info 9%
ARGX argenx NV ADR 62 50 74 29 info 24.3%
KRYS Krystal Biotech Inc 60 68 85 17 info 13.2%
PTGX Protagonist Therapeutics Inc 60 84 60 10 info 9.9%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-12

Quick answers

Who are Roivant Sciences Ltd's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Halozyme Therapeutics Inc (HALO), Argen-X (ARGX.BR), BeiGene, Ltd. (ONC), argenx NV ADR (ARGX), Krystal Biotech Inc (KRYS), Protagonist Therapeutics Inc (PTGX).

How does ROIV score against its peers?

Roivant Sciences Ltd's composite reads 36/100, ranking 7 of 7 in its cohort as of 2026-10-12; the cohort's highest composite is Halozyme Therapeutics Inc at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.